Merck & Co Inc has a consensus price target of $117.07, established from looking at the 100 latest analyst ratings. The last 3 analyst ratings were released from Berenberg, Cantor Fitzgerald, and Cantor Fitzgerald on April 8, 2024, April 5, 2024, and April 1, 2024. With an average price target of $137.67 between Berenberg, Cantor Fitzgerald, and Cantor Fitzgerald, there's an implied 9.78% upside for Merck & Co Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
04/08/2024 | MRK | Buy Now | Merck & Co | $125.40 | 14.04% | Berenberg | Luisa Hector | $140 → $143 | Maintains | Buy | Get Alert |
04/05/2024 | MRK | Buy Now | Merck & Co | $125.40 | 7.66% | Cantor Fitzgerald | Louise Chen | → $135 | Reiterates | Overweight → Overweight | Get Alert |
04/01/2024 | MRK | Buy Now | Merck & Co | $125.40 | 7.66% | Cantor Fitzgerald | Louise Chen | → $135 | Reiterates | Overweight → Overweight | Get Alert |
03/28/2024 | MRK | Buy Now | Merck & Co | $125.40 | 13.24% | Truist Securities | Robyn Karnauskas | $139 → $142 | Reiterates | Buy → Buy | Get Alert |
03/27/2024 | MRK | Buy Now | Merck & Co | $125.40 | 7.66% | Cantor Fitzgerald | Louise Chen | → $135 | Reiterates | Overweight → Overweight | Get Alert |
03/27/2024 | MRK | Buy Now | Merck & Co | $125.40 | 7.66% | Wells Fargo | Mohit Bansal | $130 → $135 | Maintains | Equal-Weight | Get Alert |
03/11/2024 | MRK | Buy Now | Merck & Co | $125.40 | -17.07% | Societe Generale | Justin Smith | → $104 | Downgrade | Hold → Sell | Get Alert |
03/11/2024 | MRK | Buy Now | Merck & Co | $125.40 | 7.66% | Cantor Fitzgerald | Louise Chen | → $135 | Reiterates | Overweight → Overweight | Get Alert |
02/29/2024 | MRK | Buy Now | Merck & Co | $125.40 | 7.66% | Cantor Fitzgerald | Louise Chen | → $135 | Reiterates | Overweight → Overweight | Get Alert |
02/14/2024 | MRK | Buy Now | Merck & Co | $125.40 | 7.66% | Cantor Fitzgerald | Louise Chen | → $135 | Reiterates | Overweight → Overweight | Get Alert |
02/05/2024 | MRK | Buy Now | Merck & Co | $125.40 | 7.66% | Cantor Fitzgerald | Louise Chen | → $135 | Reiterates | Overweight → Overweight | Get Alert |
02/02/2024 | MRK | Buy Now | Merck & Co | $125.40 | 10.85% | Truist Securities | Robyn Karnauskas | $122 → $139 | Maintains | Buy | Get Alert |
02/02/2024 | MRK | Buy Now | Merck & Co | $125.40 | 18.02% | UBS | Colin Bristow | $135 → $148 | Maintains | Buy | Get Alert |
02/02/2024 | MRK | Buy Now | Merck & Co | $125.40 | 3.67% | Wells Fargo | Mohit Bansal | $125 → $130 | Maintains | Equal-Weight | Get Alert |
02/02/2024 | MRK | Buy Now | Merck & Co | $125.40 | 15.63% | Barclays | Carter Gould | $135 → $145 | Maintains | Overweight | Get Alert |
01/23/2024 | MRK | Buy Now | Merck & Co | $125.40 | 7.66% | Barclays | Carter Gould | $130 → $135 | Maintains | Overweight | Get Alert |
01/09/2024 | MRK | Buy Now | Merck & Co | $125.40 | 7.66% | Cantor Fitzgerald | Louise Chen | → $135 | Reiterates | Overweight → Overweight | Get Alert |
01/04/2024 | MRK | Buy Now | Merck & Co | $125.40 | 7.66% | TD Cowen | Steve Scala | $125 → $135 | Upgrade | Market Perform → Outperform | Get Alert |
11/29/2023 | MRK | Buy Now | Merck & Co | $125.40 | 7.66% | Cantor Fitzgerald | Louise Chen | → $135 | Reiterates | Overweight → Overweight | Get Alert |
The latest price target for Merck & Co (NYSE: MRK) was reported by Berenberg on April 8, 2024. The analyst firm set a price target for $143.00 expecting MRK to rise to within 12 months (a possible 14.04% upside). 39 analyst firms have reported ratings in the last year.
The latest analyst rating for Merck & Co (NYSE: MRK) was provided by Berenberg, and Merck & Co maintained their buy rating.
The last upgrade for Merck & Co Inc happened on January 4, 2024 when TD Cowen raised their price target to $135. TD Cowen previously had a market perform for Merck & Co Inc.
The last downgrade for Merck & Co Inc happened on March 11, 2024 when Societe Generale changed their price target from N/A to $104 for Merck & Co Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Merck & Co, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Merck & Co was filed on April 8, 2024 so you should expect the next rating to be made available sometime around April 8, 2025.
While ratings are subjective and will change, the latest Merck & Co (MRK) rating was a maintained with a price target of $140.00 to $143.00. The current price Merck & Co (MRK) is trading at is $125.40, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.